EUVIMEDEUVIMED entdecken
LeitlinieQuerschnittstudie

The potential impact of ACOG guideline changes on genital melanoma detection rates in females: a retrospective cross-sectional analysis and implications for clinical practice

Kritin K Verma, Danita Mathew, Mary Fitzgibbon, Daniel P Friedmann, Ethan Matthew, Michelle B Tarbox, Theodore Rosen

Archives of Dermatological Research · 2025

DOI: 10.1007/s00403-025-03960-2 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Kritin K Verma und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Texas Tech University Health Sciences Center, 3601 4th St, Lubbock, TX, 79430, USA. kritin.k.verma@ttuhsc.edu. Hauptthemen laut MEDLINE: Melanoma, Practice Guidelines as Topic, Vulvar Neoplasms, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genital melanoma (GM) is a rare but aggressive cancer that accounts for less than 5% of vaginal cancers and 0.2-0.8% of all melanomas in the United States. The 2018 American College of Obstetricians and Gynecologists (ACOG) guidelines reduced routine pelvic exams for women aged 65 and older, raising concerns about later-stage GM diagnosis, worse survival rates, and potential underreporting. This study investigated the impact of these guideline changes on female GM detection rates through a cross-sectional analysis of female patients aged 18 and older in the All of Us database from 2012 to 2023. The analysis focused on melanoma in-situ (MIS) of the vulva using ICD-10-CM code D03.8 to calculate prevalence and incidence. The study identified 16 cases of vulvar MIS (0.006%, 95% CI [0.004-0.010%]) with a mean age of 64.6 ± 12.4 years at diagnosis. Prevalence peaked in the 61-70 age group (0.014%, 95% CI [0.000-0.029%]), with white patients showing the highest prevalence (0.009%, 95% CI [0.004-0.015%]). The overall incidence was 5.37 cases per million women per year. However, a decreasing trend was observed, with no cases reported between 2021 and 2023. This decline in reported cases may be linked to the 2018 ACOG guideline changes, potentially leading to later-stage diagnoses and poor outcomes. The study's limitations include the inability to calculate yearly incidence due to lack of annual enrollment data and the absence of staging information. The findings suggest a potential connection between the ACOG guideline modifications and GM detection rates. While current incidence rates are similar to or higher than those before the 2018 changes, the decline in routine pelvic exams may contribute to later-stage diagnoses and poor outcomes. The absence of diagnosed GM cases in the past three years is particularly concerning and may reflect delayed effects of infrequent screening. Increased awareness, improved screening practices, and additional research are necessary to fully understand the impact of the 2018 ACOG guideline changes on GM diagnosis and treatment. Healthcare providers should consider performing yearly pelvic examinations, especially for patients over 65, while educating patients on early self-detection of GM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaPractice Guidelines as TopicVulvar NeoplasmsEarly Detection of CancerSkin NeoplasmsHumansFemaleMiddle AgedCross-Sectional StudiesAgedRetrospective StudiesUnited StatesIncidencePrevalenceAdultAged, 80 and overYoung Adult

Stichwörter der Autor:innen

ACOG guidelinesEarly detectionFemale populationsGenital melanomaIncidencePrevalenceScreening practicesVulvar cancer

Autor:innen und Institutionen

  • School of Medicine, Texas Tech University Health Sciences Center, 3601 4th St, Lubbock, TX, 79430, USA. kritin.k.verma@ttuhsc.edu.
  • School of Medicine, Texas Tech University Health Sciences Center, 3601 4th St, Lubbock, TX, 79430, USA.
  • Department of Pediatrics, WashU Medicine, St. Louis, MO, USA.
  • Westlake Dermatology Clinical Research Center, Westlake Dermatology & Cosmetic Surgery, Austin, TX, USA.
  • Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
  • Department of Dermatology, Baylor College of Medicine, Houston, TX, USA.

Zitieren

APA

Verma, K. K., Mathew, D., Fitzgibbon, M., Friedmann, D. P., Matthew, E., Tarbox, M. B., & Rosen, T. (2025). The potential impact of ACOG guideline changes on genital melanoma detection rates in females: a retrospective cross-sectional analysis and implications for clinical practice. Archives of Dermatological Research. https://doi.org/10.1007/s00403-025-03960-2

Vancouver

Verma KK, Mathew D, Fitzgibbon M, Friedmann DP, Matthew E, Tarbox MB, et al. The potential impact of ACOG guideline changes on genital melanoma detection rates in females: a retrospective cross-sectional analysis and implications for clinical practice. Archives of Dermatological Research. 2025. doi:10.1007/s00403-025-03960-2

BibTeX
@article{Verma2025,
  author = {Verma, Kritin K and Mathew, Danita and Fitzgibbon, Mary and Friedmann, Daniel P and Matthew, Ethan and Tarbox, Michelle B and Rosen, Theodore},
  title = {The potential impact of ACOG guideline changes on genital melanoma detection rates in females: a retrospective cross-sectional analysis and implications for clinical practice},
  journal = {Archives of Dermatological Research},
  year = {2025},
  doi = {10.1007/s00403-025-03960-2}
}
Kostenlos starten →